A 32-year-old man from rural Odisha presents with fever for 3 days, chills, and myalgia. On examination, he is febrile (39.2°C), with hepatosplenomegaly and mild jaundice. Thick and thin blood smears show P. vivax trophozoites. His haemoglobin is 11.2 g/dL, platelet count 95,000/μL, and serum creatinine 1.8 mg/dL. What is the most appropriate immediate next step in management?

Explanation

## Clinical Assessment This patient presents with **P. vivax malaria with warning signs of severity**: elevated creatinine (1.8 mg/dL, indicating acute kidney injury), thrombocytopenia (95,000/μL), and jaundice. These features meet WHO criteria for **severe malaria** despite the absence of cerebral involvement or pulmonary oedema at presentation. ## Management Algorithm ```mermaid flowchart TD A[Confirmed malaria parasitaemia]:::outcome --> B{Severity assessment}:::decision B -->|Uncomplicated| C[Oral artemisinin-based combination therapy]:::action B -->|Warning signs present| D[Renal impairment, thrombocytopenia, jaundice]:::urgent D --> E[Meets severe malaria criteria]:::outcome E --> F[IV artesunate 2.4 mg/kg at 0, 12, 24 hrs, then daily]:::action F --> G[Switch to oral ACT when able to tolerate]:::action ``` ## Key Point **Key Point:** WHO 2023 guidelines mandate **parenteral artesunate as first-line therapy for all severe malaria**, regardless of Plasmodium species. This includes P. vivax with complications. ## Why Artesunate IV? | Feature | Artesunate IV | Chloroquine | Artemether IM | |---------|--------------|------------|---------------| | **Onset** | Rapid (parasitaemia reduction within 4 hrs) | Slow (24–48 hrs) | Slower than IV | | **Severe malaria indication** | First-line (WHO) | Contraindicated in severe cases | Second-line only | | **Mortality reduction** | 35% vs quinine [cite:WHO 2023] | No benefit in severe disease | Inferior to artesunate | | **Renal safety** | Safe; no dose adjustment needed | Accumulates in renal failure | Requires IM route | ## Clinical Pearl **Clinical Pearl:** Elevated creatinine (1.8 mg/dL) in acute malaria signals **acute kidney injury** — a hallmark of severe malaria. Chloroquine is contraindicated because it accumulates in renal failure and increases toxicity risk. Artesunate is the only artemisinin derivative with proven mortality benefit in severe malaria. ## High-Yield **High-Yield:** P. vivax can cause severe malaria with organ dysfunction just as P. falciparum can. Do NOT assume P. vivax is always benign. Presence of **any one** of the following mandates IV artesunate: - Serum creatinine >3 mg/dL or urine output <400 mL/24 hrs - Platelet count <50,000/μL - Jaundice (bilirubin >3 mg/dL) - Cerebral malaria, severe anaemia, pulmonary oedema, metabolic acidosis ## Warning **Warning:** Chloroquine monotherapy is obsolete for severe malaria and increases mortality. Oral ACTs are inappropriate when the patient cannot tolerate oral intake or has organ dysfunction.